Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well as neurology. BridGene’s pursuit of undruggable targets is enabled ...

Takeda’s (NYSE: TAK) (TSE:4502) plasma-derived therapies (PDT) business, led by Giles Platford, president of Takeda’s Plasma-Derived Therapies Business Unit and chair of the Plasma Protein ...

ICC Champions Trophy 2025 Opening Ceremony: Although the first match of the ICC Champions Trophy 2025 has yet to begin, the global event officially kicked off at Lahore Fort in Pakistan on Sunday ...

The ICC Champions Trophy is just a day away and fans are going berserk with all the excitement, which is evident from the reels and posts doing the rounds of social media. All eyes are on the ...

In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other Japanese stocks. As the dangers of natural disasters increase and ...

Team India has lost 15 consecutive tosses in ODIs till date. Despite this streak, India reached the ICC Champions Trophy final against New Zealand in Dubai.

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...

The ICC Champions Trophy is being revived after eight years with holders and hosts Pakistan playing New Zealand in the opening game of the ninth edition on Wednesday (February 19, 2025).

The biggest stories of the day delivered to your inbox.

As we stand on the brink of the ICC Men’s Champions Trophy 2025, several sides will be donning new stripes going into the tournament. India's familiar hue of blue will also have the addition of a ...

All the teams in the group stage will be playing each other once. For a win, two points will be awarded while the teams will share one point each if a result is not possible in a match. In case ...

On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.